TargetMol

NSC 109555

Product Code:
 
TAR-T33737
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T33737-100mg100mg£1,067.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
0
CAS:
15427-93-7
Formula:
C21H32N10O7S2
Molecular Weight:
600.67
Purity:
0.98
SMILES:
CS(O)(=O)=O.CS(O)(=O)=O.CC(=N/N=C(N)N)c1ccc(NC(=O)Nc2ccc(cc2)C(C)=NN=C(N)N)cc1

References

Zhu L, Zhao L, Wang H, Wang Y, Pan D, Yao J, Li Z, Wu G, Guo Q. Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest. Toxicol Lett. 2013 May 23;219(2):107-15. doi: 10.1016/j.toxlet.2013.01.019. Epub 2013 Mar 5. PubMed PMID: 23470866. Lountos GT, Tropea JE, Zhang D, Jobson AG, Pommier Y, Shoemaker RH, Waugh DS. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor. Protein Sci. 2009 Jan;18(1):92-100. doi: 10.1002/pro.16. PubMed PMID: 19177354; PubMed Central PMCID: PMC2708046. Gogineni VR, Nalla AK, Gupta R, Dinh DH, Klopfenstein JD, Rao JS. Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells. Cancer Lett. 2011 Dec 26;313(1):64-75. doi: 10.1016/j.canlet.2011.08.022. Epub 2011 Sep 6. Erratum in: Cancer Lett. 2014 Jul 28;349(2):155. PubMed PMID: 21945852; PubMed Central PMCID: PMC3196767. Jobson AG, Lountos GT, Lorenzi PL, Llamas J, Connelly J, Cerna D, Tropea JE, Onda A, Zoppoli G, Kondapaka S, Zhang G, Caplen NJ, Cardellina JH 2nd, Yoo SS, Monks A, Self C, Waugh DS, Shoemaker RH, Pommier Y. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther. 2009 Dec;331(3):816-26. doi: 10.1124/jpet.109.154997. Epub 2009 Sep 9. PubMed PMID: 19741151; PubMed Central PMCID: PMC2784710.